Pierre Gourdy, Patrice Darmon, Isabelle Borget, Corinne Emery, Isabelle Bureau, Bruno Detournay, Amar Bahloul, Noemie Allali, Aymeric Mahieu, Alfred Penfornis
INTRODUCTION: Second-generation basal insulins like glargine 300 U/mL (Gla-300) have a longer duration of action and less daily fluctuation and interday variability than first-generation ones, such as glargine 100 U/mL (Gla-100). The EF-BI study, a nationwide observational, retrospective study, was designed to compare persistence, acute care complications, and healthcare costs associated with the initiation of such basal insulins (BI) in a real-life setting in France. METHODS: This study was conducted using the French healthcare claims database (SNDS)...
April 20, 2024: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders